WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
FierceBiotech | March 06, 2020
The Fred Hutchinson Cancer Research Center is making its Seattle-based staff work from home in light of the emergence of a cluster of coronavirus cases in the city. The precautionary action comes as biopharma companies are starting to pull back from face-to-face events to cut the risk of their employees catching the virus. As of Thursday, all of Fred Hutch’s Seattle-based employees, bar security and other staff that need to be on campus, are working remotely. Fred Hutch plans to keep the m...
Thermo Fisher Scientific | May 24, 2022
Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally.
Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using w...
CELL AND GENE THERAPY
2seventy bio, Inc | January 07, 2022
2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...
BioSpace | February 25, 2020
TwinStrand Biosciences™, a next-generation DNA sequencing technology company, today announced the launch of TwinStrand Duplex Sequencing™ Technology kits at the annual Advances in Genome Biology and Technology (AGBT) General Meeting in Marco Island, Florida. At launch, the company will offer their platform technology for two research applications: detection of minimal residual disease in acute myeloid leukemia patients (AML MRD) and a multi-species genetic toxicology assay for rapid ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE